Event-Driven Stocks

PLx Pharma Winddown Corp.

Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕

Signs3 good3 warning1 severedetails ↓

Financials

SEC XBRL · annual
 FY21FY20FY19FY18FY17FY16
Revenue$8.2M$30,000$565,464$753,108$778,657$20,000
Operating income−$40.8M−$13.5M−$14.2M−$11.0M−$15.8M−$4.8M
Net income−$46.1M−$15.2M−$20.5M$896,480−$15.3M−$4.9M
Total assets$76.6M$26.6M$18.5M$18.4M$28.8M$616,488
Total liabilities$25.0M$16.2M$16.9M$11.9M$24.2M$2.9M
Equity$35.7M−$10.9M−$12.1M$6.4M$4.6M−$2.3M
EPS (diluted)$9714951.00$8916190.00$0.10$-2.19
Shares out.21.8M9.2M8.8M8.7M11.1M10.4M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2021
Operating margin
−497.0%
Net margin
−562.0%
Return on equity
−129.3%
Return on assets
−60.2%
Return on capital (ROCE)
−63.0%
Liabilities / assets
32.6%
Debt / equity
0.70×
Book value / share
$1.64
Revenue growth (YoY)
27260.0%
Net income growth (YoY)

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2021
Altman Z″ (distress)
-3.11distress
Accruals / assets
18.3%clean
Piotroski F-Score
4/9mixed

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
62
/ 100
Profitability 0Growth 100Catalyst 67Earnings quality 67Financial strength 75

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

1 severe3 warning3 good
  • Altman Z″ in the distress zone
  • Operating losses (negative operating margin)
  • Reported a net loss
  • Negative operating cash flow
  • Revenue is growing year-over-year
  • Conservative leverage (liabilities < 50% of assets)
  • Clean earnings (low accruals)

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Insider transactions

SEC Form 4 · most recent
3 acquisitions0 disposals3 open-market buy(s)net +15,300 shares · last 3
InsiderDateTypeSharesPrice
Giordano NatashaOfficer — Chief Executive OfficerMar 15, 2022Buy4,100$3.65
O'Connor Rita MOfficer — Chief Financial OfficerMar 15, 2022Buy10,000$3.66
Valentino Michael JOfficer — Executive ChairmanJun 14, 2021Buy1,200$12.44

Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (1)

Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.